Abstract
Classical and basal-like transcriptional subtypes of pancreatic ductal adenocarcinoma (PDAC) are prognostic and may predict response to different chemotherapy regimens and RAS inhibitors. Current subtyping methods rely on tissue biopsies and remain challenging to integrate into clinical workflows. Herein, we present a novel approach for non-invasive subtyping of PDAC based on epigenomic profiling of circulating tumor DNA (ctDNA). In a multi-omics cohort of patient-derived xenografts, we identify highly recurrent regulatory elements associated with classical and basal-like PDAC. We then demonstrate that these epigenomic signatures can identify PDAC subtype from plasma epigenomic profiling in a multi-institutional cohort of patients with metastatic PDAC and integrate information from circulating histone modifications and DNA methylation to develop the Pancreatic Integrated Epigenomic Score (PIES). PIES is concordant with tissue-based labels and captures transcriptional subtype heterogeneity observed within biopsies. Furthermore, it improves prognostication over tissue-based subtyping suggestive of the recovery of ground truth tumor biology from plasma ctDNA. Our work provides a proof-of-concept for a circulating biomarker that enables transcriptional subtyping and informs therapeutic decisions in pancreatic cancer.
Significance
Transcriptional subtyping of pancreatic cancer can improve prognostication and inform treatment selection. Current subtyping approaches rely on tissue biopsy, are challenging to implement in clinical practice, and are limited by tumor heterogeneity and sampling error. Herein, we introduce a cell-free DNA-based epigenomic assay capable of inferring pancreatic cancer subtypes noninvasively.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.
